LATEST NEWS
02.02.2012
San Diego: CalAsia Pharmaceuticals and Professor R. Padmanabhan of Georgetown University announce a collaboration to develop inhibitors of Dengue and West Nile virus protoeases.
View Full Article
TECHNOLOGY
Lead Optimization
CalAsia Pharmaceuticals approach for discovering drug candidates efficiently is to introduce selectivity and specificity from the very early stage of hit identification and improve it further during lead optimization. This approach recues the failure rates of the drug candidates at the more advanced and expensive stages of drug discovery and development. To this end, we have been using differential screening method (DFS).
- Differential fragment-based screening (DFS) technology platform was developed by the experienced founding team of CalAsia
- DFS addresses the fundamental problem of specificity and selectivity associated with drug discovery process
- Combined with Structure-based methods, DFS helps the drug discovery world in developing New Chemical Entities (NCEs) that are highly specific and selective
- DFS uses “Dial in Dial out” mechanism to effectively introduce specificity and tease out affinities towards off-targets, thereby minimizing the risks of toxicity and side-effects related to off-species interactions at the very early stage of lead optimization
- This approach significantly minimizes the attrition at the latter expensive stages of preclinical and clinical drug development process
Differential Fragment-Based Screening (DFS)
Combining DFS with iterative structure based design is a powerful tool to rapidly discover potent and selective lead compounds. CalAsia has discovered low nanomolar efficacy compounds in the very first iteration using this approach.
Our team of expert scientists have extensive knowledge of developing cell-based assays for evaluating drug candidates for efficacy and selectivity.
Our additional capabilities include characterization of compounds for CNS permeability, microsomal and plasma stability and other surrogate ADME studies.
In partnership with our external CRO we can design and execute in vivo Pharmacokinetics and Pharmacodynamics studies in normal and relevant animal models.